Edgen Stock·Dec 19 2025, 02:10Back
Lilly Submits Oral Obesity Drug to FDA After Trial Shows Weight-Loss Maintenance
Edgen Stock·Dec 19 2025, 02:10
[1] Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial - Eli Lilly (https://investor.lilly.com/news-releases/news ...)[2] Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial - Eli Lilly (https://investor.lilly.com/news-releases/news ...)
